Trained microbiologist and synthetic biologist with a background in organic chemistry. I work at the interface of microbiome research, synthetic biology, and next-generation sequencing. I want to develop the next generation of whole cell therapeutics to treat chronic microbial diseases.Summary- Co-founder and CEO of skin microbiome company, Phi Therapeutics- Developed relationships with microbiome and dermatology KOLs in academia and industry- Deep understanding of the safety and regulatory landscape in dermatology for both cosmetic and therapeutic products- Successfully applied for patents (3), an academic fellowship (1) and an industry grant (1)- Unique mix of critical, analytical and multidisciplinary thinking that drives insight- Skilled in communicating scientific concepts in oral and written formats- Thrive in a dynamic, challenging, and diverse environment- Experience in multi-group collaborations, project management, managing a team of scientists - 7 years of combined post-doctoral and industry experience as microbiome and synthetic biologist- Productive independent microbiologist: extensive training in next-gen sequencing (NGS) and managing large datasets, synthetic biology, and metabolic engineering.Laboratory ExperienceSynthetic Biology: Large-scale gene cluster assembly from multiple fragments, RBS and promoter optimizationCell and Molecular Biology: cell culture (endothelial and epithelial cells), enzyme kinetics, skin punch biopsies, flow cytometry, cytokine bead analysis, and cloningSequencing: Next-gen sequencing (NGS), bacterial whole genome sequencing, 16S profiling, RNASeqBiochemistry: Western blots, protein purification, mass spectrometry (GC-MS, LC-MS), bioconjugation.